Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2006-05-23
2006-05-23
O'Hara, Eileen B. (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S387300, C536S023500, C514S012200, C435S069100, C435S069700, C435S320100, C435S252300, C435S361000, C424S192100
Reexamination Certificate
active
07049402
ABSTRACT:
The present invention relates to a novel human gene encoding a polypeptide which is a member of the TNF receptor family, and has now been found to bind TRAIL. More specifically, an isolated nucleic acid molecule is provided encoding a human polypeptide named tumor necrosis factor receptor-5, sometimes referred to as “TNFR-5” or “TR5,” and now referred to hereinafter as “TRAIL receptor without intracellular domain” or “TRID.” TRID polypeptides are also provided, as are vectors, host cells, and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists or antagonists of TRAIL polypeptide activity. Also provided are diagnostic and therapeutic methods utilizing such compositions.
REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5349053 (1994-09-01), Landolfi
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5478925 (1995-12-01), Wallach et al.
patent: 5783672 (1998-07-01), Mosley et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 6261801 (2001-07-01), Wei et al.
patent: 2002/0102706 (2002-08-01), Ashkenazi et al.
patent: 2002/0161202 (2002-10-01), Ashkenazi et al.
patent: 2003/0138915 (2003-07-01), Ashkenazi et al.
patent: 2045869 (1991-12-01), None
patent: 0 239 400 (1987-09-01), None
patent: 0 867 509 (1998-09-01), None
patent: WO 91/06570 (1991-05-01), None
patent: WO 94/01548 (1994-01-01), None
patent: WO 9401548 (1994-01-01), None
patent: WO 98/30693 (1998-07-01), None
patent: WO 98/32856 (1998-07-01), None
patent: WO 98/58062 (1998-12-01), None
patent: WO 99/00423 (1999-01-01), None
patent: WO 99/09165 (1999-02-01), None
patent: WO 99/46287 (1999-09-01), None
Hillier et al., Database EST, Accession No. AA150541, May 19, 1997.
Wallach, D. (2000) TNF ligand and TNF/NGF receptor families. In: Cytokine Reference (Joost J. Oppenheim and Marc Feldmann editors in chief, Academic Press (London), 377-411.
Huston, J.S., et al., “Protein Engineering of Single-Chain Fv Analogs and Fusion Proteins,”Methods in Enzymol: 203:46-88, Academic Press, Inc. (1991).
MacFarlane, M., et al., “Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL,”J. Biol. Chem. 272:25417-25420, The American Society for Biochemistry and Molecular Biology, Inc. (1997).
Morrison, S.L., “Transfectomas Provide Novel Chimeric Antibodies,”Science 229:1202-1207, American Association for the Advancement of Science (1985).
Pan, G., et al., “An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL,”Science 277:815-818, American Association for the Advancement of Science (1997).
Pitti, R.M., et al., “Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family,”J. Biol. Chem. 271:12687-12690, The American Society for Biochemistry and Molecular Biology, Inc. (1996).
Schneider, P., et al., “Characterization of two receptors for TRAIL,”FEBS Letters 416:329-334, Federation of European Biochemical Societies (1997).
Sheridan, J.P., et al., “Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors,”Science 277:818-821, American Association for the Advancement of Science (1997).
Wiley, S.R., et al., “Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis,”Immunity 3:673-682, Cell Press (1995).
GenBank Accession No. T71272, Hillier, L. et al., Mar. 15, 1995.
GenBank Accession No. T71406, Hillier, L. et al., Mar. 15, 1995.
GenBank Accession No. R10995, Hillier, L. et al., Apr. 11, 1995.
GenBank Accession No. R10996, Hillier, L. et al., Apr. 11, 1995.
GenBank Accession No. G23178, Hudson, T., May 31, 1996.
GenBank Accession No. AA031883, Hillier, L. et al., Aug. 21, 1996.
GenBank Accession no. AA150849, Hillier, L. et al., May 19, 1997.
GenBank Accession No. AA150541, Hillier, L. et al., May 19, 1997.
GenBank Accession No. AF012536, Sheridan, J.P. et al., Aug. 21, 1997.
GenBank Accession No. AF012629, Pan, G. et al., Aug. 21, 1997.
GenBank Accession No. AF033854, Mongkoisapaya, J. et al., Nov. 27, 1997.
GenBank Accession No. AF014794, Degli-Esposti, M.A. et al., Mar. 12, 1998.
GenBank Accession No. AF020502, MacFarlane, M. et al., Sep. 28, 1997.
GenBank Accession No. AF016267, Schneider, P. et al., Oct. 16, 1997.
Co-Pending U.S. Appl. No. 09/573,986, filed May 18, 2000.
Pending Non-Provisional U.S. Appl. No. 09/912,292, filed Jul. 26, 2001, pp. 1-75 (pp. 1 and 2 partially redacted); portion of Table 2; and SEQ ID Nos. 40587, 12875, and 53156 (Not Published).
Pending Non-Provisional U.S. Appl. No. 09/912,293, filed Jul. 26, 2001, pp. 1-75 (pp. 1 and 2 partially redacted); portion of Table 2; and SEQ ID No. 194270 (Not Published).
Badley, A.D., et al., “Upregulation of Fas Ligand Expression by Human Immunodeficiency Virus in Human Macrophages Mediates Apoptosis of Uninfected T Lymphocytes,”J. Virol. 70:199-206, American Society for Microbiology (Jan. 1996).
Han, L.-H., et al., “Detection of soluble TRAIL in HBV infected paients and its clinical implications,”World J. Gastroenterol. 8:1077-1080, The WJG Press (Dec. 2002).
Jeremias, I., et al., “TRAIL/Apo-2-ligand-induced apoptosis in human T cells,”Eur. J. Immunol. 28:143-152, Wiley-VCH Verlag GmbH (Jan. 1998).
Miura, Y., et al., “Critical Contribution of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) to Apoptosis of Human CD4+T Cells in HIV-1-infected hu-PBL-NOD-SCID Mice,”J. Exp. Med. 193:651-659, The Rockefeller University Press (Mar. 2001).
Miura, Y. and Koyanagi, Y., “Death ligand-mediated apoptosis in HIV infection,”Rev. Med. Virol. 15:169-178, John Wiley & Sons, Ltd. (Mar. 2005).
Okada, H., et al., “Extensive lymphopenia due to apoptosis of uninfected lymphocytes in acute measles patients,”Arch. Virol. 145:905-920, Springer-Verlag (May 2000).
Roe, M.F.E., et al., “Lymphocyte apoptosis in acute respiratory syncytial virus bronchiolitis,”Clin. Exp. Immunol. 137:139-145, Blackwell Publishing Ltd. (Jul. 2004).
Secchiero, P., et al., “Human herpesvirus 7 induces the functional up-regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) coupled to TRAIL-R1 down-modulation in CD4+T cells,”Blood 98:2474-2481, The American Society of Hematology (Oct. 2001).
Gentz Reiner
Ni Jian
Ruben Steven M
Wei Ying-Fei
Human Genome Sciences Inc.
O'Hara Eileen B.
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Tumor necrosis factor receptor-5 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor necrosis factor receptor-5, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor necrosis factor receptor-5 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3581582